Table 1.

Comparison of breast tumor growth between different temporal BSp treatment groups in two transgenic mouse models

Animal experimental designaPrevention rate (%) in SV40 micebInhibition rate (%) in SV40 micecRatio of extended tumor latency (%) in SV40 micedMetastasis rate (%) in SV40 miceaPrevention rate (%) in Her2/neu micebInhibition rate (%) in Her2/neu micecRatio of extended tumor latency (%) in Her2/neu micedMetastasis rate (%) in Her2/neu mice
Prenatal/maternal BSp25e56.93f10.34g1050h37.1g30.83f15
Postnatal early-life BSp14.248.6g4.914.220g27.218.8g15
Postnatal adult BSp103.570.52200−6.38−2.9530
  • aPrevention rate (%) = tumor-free mice number/total mice number.

  • bInhibition rate on tumor growth (IR) = [1 − (mean tumor weight at sacrifice of the treatment group)/(mean tumor weight at sacrifice of the control group)] · 100.

  • cRatio of extended tumor latency (%) = (tumor latency in BSp group − tumor latency in control group)/tumor latency in control group.

  • dMetastasis cases include direct invasion such as adjacent lymph nodes and skeletal muscle (stage III) and remote metastasis such as lung metastasis (stage IV).

  • eP < 0.01.

  • fP < 0.001.

  • gP < 0.05, significantly different from the control group.

  • hP < 0.0001.